Development and Validation of Stability Indicating Method for Estimation of Buparvaquone by Forced Degradation Studies

Abstract

Aim: A lucid, rapid and precise stability-indicating method was developed by using HPLC for the estimation of Buparvaquone in bulk as well as pharmaceutical dosage form by forced degradation studies. Materials and Methods: Princeton C 18 column (4.6 × 150 mm, 5µ) and mobile phase containing 1% glacial acetic acid and acetonitrile in the proportion of 5:95 v/v was used throughout the study. The flow rate was 0.9 ml/m and the detecting wavelength was kept as 251 nm using the PDA detector. Results: The retention time of Buparvaquone was found to be at 8.6 ± 0.5 m. The method developed was validated, as stated in ICH Q2 (R1) guidelines. It was found to be linear within concentration ranging from 2-20 µg/ml having a correlation coefficient 0.999 and other parameters are also under permissible limits. Conclusion: Buparvaquone was exposed to different stress conditions like acidic, basic, neutral, thermal, peroxide and also photolytic. Amongst all, the drug was found to be more degraded under basic as well as peroxide conditions.

Development and Validation of Novel Ultraviolet Spectrophotometric Method for Estimation of Antileishmanial Drug Buparvaquone

“…Literature survey discloses that there are specific techniques available for the estimation of buparvaquone like Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method, bioanalytical method and spectrofluorimetric method [14][15][16] . The current study was designed to develop a cheap, novel accurate and precise Ultraviolet (UV) method [17] This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms…”